Beam Therapeutics/$BEAM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Beam Therapeutics
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
Ticker
$BEAM
Sector
Primary listing
Employees
522
Headquarters
Website
BEAM Metrics
BasicAdvanced
$3.4bn
-
-$0.64
2.26
-
Price and volume
Market cap
$3.4bn
Beta
2.26
52-week high
$36.44
52-week low
$15.60
Average daily volume
2m
Financial strength
Current ratio
16.991
Quick ratio
16.25
Long term debt to equity
20.271
Total debt to equity
21.54
Profitability
EBITDA (TTM)
-349.251
Gross margin (TTM)
-146.90%
Net profit margin (TTM)
-40.23%
Operating margin (TTM)
-226.58%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
-15.76%
Return on equity (TTM)
-5.77%
Valuation
Price to revenue (TTM)
21.383
Price to book
2.91
Price to tangible book (TTM)
2.91
Price to free cash flow (TTM)
-9.137
Free cash flow yield (TTM)
-10.94%
Free cash flow per share (TTM)
-3.737
Growth
Revenue change (TTM)
157.97%
Earnings per share change (TTM)
-86.06%
3-year revenue growth (CAGR)
28.83%
3-year earnings per share growth (CAGR)
-47.59%
What the Analysts think about BEAM
Analyst ratings (Buy, Hold, Sell) for Beam Therapeutics stock.
BEAM Financial Performance
Revenues and expenses
BEAM Earnings Performance
Company profitability
BEAM News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs